| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Customized |
|
Still deciding? Get samples of $ !
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
|
|
Melanotan II (CAS NO.121062-08-6) was first synthesized at the University of Arizona. Researchers decided to find a more potent and stable alternative, one that would be more practical to defend against skin cancer.
The researchers headed by Victor Hruby found a peptide, [Nle4, D-Phe7]-α-MSH, that was approximately 1,000 times more potent than natural α-MSH after synthesizing andscreening hundreds of molecules. They dubbed this new peptide, "Melanotan" (later Melanotan I, now known as afamelanotide). They subsequently developed another analog, Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2), which they named "Melanotan Acetate".
Since their discovery, numerous studies dating back to the mid-1980s have found no obvious toxic effects of the Melanotan peptides. The scientists hoped to use Melanotan peptides to combat melanoma by stimulating the body's natural tanning mechanism to create a tan without first needing exposure to harmful levels of UV radiation. This in turn, they hypothesized, could reduce the potential for skin damage that can eventually lead to skin cancer.
Ethical debates surround MT-2 use, including considerations of body modification, natural beauty ideals, and commercialization of cosmetic enhancements. Exploring these perspectives fosters ethical awareness.
Users should be cautious when combining MT-2 with other medications, as interactions could occur. Consulting a healthcare provider is advisable to ensure safety and efficacy when using MT-2 alongside other treatments.
Beyond aesthetics, MT-2 is sometimes used by athletes to enhance muscle definition. Its ability to darken the skin can accentuate muscle tone, but its impact on athletic performance beyond visual appearance is limited.
|
|
){kind=link}